Case Report: Cholangiocarcinoma and Hypercalcemia

Davis, James H.; Sadasivan, Raj; Dwyer, Tim; Veldhuizen, Peter J. Van

doi:10.1097/00000441-199405000-00008

Cited by 27 publications

(17 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy for cholangiocarcinoma is administered to those patients who are not operative and results have been largely disappointing, especially for cholangiocarcinoma that produces PTHrP [4, 16]. To the best of our knowledge, patients diagnosed with a PTHrP-secreting cholangiocarcinoma who lived for more than six months have been reported in only four instances, including the present case (Table 2) [4, 17, 18]; chemotherapy was performed for each case but surgical resection was not. This suggests the possibility that chemotherapy is one of the effective treatments for a PTHrP-secreting cholangiocarcinoma, like a non-PTHrP-secreting cholangiocarcinoma.…”

Section: Discussionmentioning

confidence: 89%

Humoral Hypercalcemia of Malignancy with a Parathyroid Hormone-Related Peptide-Secreting Intrahepatic Cholangiocarcinoma Accompanied by a Gastric Cancer

Takeda

Kimura

Nishigaki

et al. 2017

Case Reports in Endocrinology

View full text Add to dashboard Cite

Humoral hypercalcemia of malignancy (HHM) is caused by the oversecretion of parathyroid hormone-related peptide (PTHrP) from malignant tumors. Although any tumor may cause HHM, that induced by intrahepatic cholangiocarcinoma (ICC) or gastric cancer (GC) is rare. We report here a 74-year-old male who displayed HHM with both ICC and GC and showed an elevated serum PTHrP level. Treatment of the hypercalcemia with saline, furosemide, elcatonin, and zoledronic acid corrected his serum calcium level and improved symptoms. Because treatment of ICC should precede that of GC, we chose chemotherapy with cisplatin (CDDP) and gemcitabine (GEM). Chemotherapy reduced the size of the ICC and decreased the serum PTHrP level. One year after diagnosis, the patient was alive in the face of a poor prognosis for an ICC that produced PTHrP. Immunohistochemical staining for PTHrP was positive for the ICC and negative for the GC, leading us to believe that the cause of the HHM was a PTHrP-secreting ICC. In conclusion, immunohistochemical staining for PTHrP may be useful in discovering the cause of HHM in the case of two cancers accompanied by an elevated serum PHTrP level. Chemotherapy with CDDP and GEM may be the most appropriate treatment for a PTHrP-secreting ICC.

show abstract

Section: Discussionmentioning

confidence: 89%

Humoral Hypercalcemia of Malignancy with a Parathyroid Hormone-Related Peptide-Secreting Intrahepatic Cholangiocarcinoma Accompanied by a Gastric Cancer

Takeda

Kimura

Nishigaki

et al. 2017

Case Reports in Endocrinology

View full text Add to dashboard Cite

show abstract

“…Although chemotherapy for CCC is administered to those patients who are not operable, the results are largely disappointing (3), especially for CCC producing PTHrP (Table 1) (2,(4)(5)(6)(7).…”

Section: Cholangiocellular Carcinoma (Ccc) Is Well Known As a Malignamentioning

confidence: 99%

Cholangiocarcinoma Producing Parathyroid Hormone-related Peptide Treated with Chemoradiation Using Gemcitabine and S-1

Yamada

Shiroeda

et al. 2009

Intern. Med.

View full text Add to dashboard Cite

show abstract

“…Parathyroid hormone‐related peptide (PTHrP) is one of the major causal factors in the pathophysiology of humoral hypercalcemia of malignancy (HHM). 1,2 Humoral hypercalcemia of malignancy caused by PTHrP has rarely been documented in patients with cholangiocellular carcinoma (CCC) 3 . There have so far been no reports of CCC associated with extensive calcification of the tumors with psammoma body formation.…”

Section: Introductionmentioning

confidence: 99%

Parathyroid hormone‐related peptide producing cholangiocellular carcinoma with a marked psammoma formation

Yamada

Sanefuji²,

Morimoto

et al. 2000

J of Gastro and Hepatol

View full text Add to dashboard Cite

Humoral hypercalcemia caused by parathyroid hormone-related peptide (PTHrP), associated with cholangiocellular carcinoma (CCC), has rarely been documented. There have been no reports of CCC associated with extensive calcification of the tumor with psammoma body formation. A 66-year-old man was admitted with a large calcified tumor in the liver detected on an abdominal X-ray. An ultrasound-guided fine needle biopsy specimen of the liver tumor showed evidence of adenocarcinoma. He had hypercalcemia with an elevated PTHrP level. The patient died because of disseminated intravascular coagulation and progressive hepatic failure. A postmortem examination revealed a large poorly differentiated CCC in the liver. Immunohistochemical examination showed the presence of PTHrP-positive tumor cells. The calcified lesion consisted of a number of accumulated psammoma bodies. We present a case of PTHrP producing CCC with a marked psammoma formation.

show abstract

Case Report: Cholangiocarcinoma and Hypercalcemia

Cited by 27 publications

References 6 publications

Humoral Hypercalcemia of Malignancy with a Parathyroid Hormone-Related Peptide-Secreting Intrahepatic Cholangiocarcinoma Accompanied by a Gastric Cancer

Humoral Hypercalcemia of Malignancy with a Parathyroid Hormone-Related Peptide-Secreting Intrahepatic Cholangiocarcinoma Accompanied by a Gastric Cancer

Cholangiocarcinoma Producing Parathyroid Hormone-related Peptide Treated with Chemoradiation Using Gemcitabine and S-1

Parathyroid hormone‐related peptide producing cholangiocellular carcinoma with a marked psammoma formation

Contact Info

Product

Resources

About